BIOTECH GROWTH N V - 19 Mar 2025 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Reporting relationship: 10%+ Owner
Issuer ticker: BDTX
Reported as of: 19 Mar 2025
Net transaction value: -$11,997,749
SEC form: 4
Accepted by SEC: 20 Mar 2025, 21:01:40 UTC
Prior SEC filing: 05 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Ivo Betschart

Key filing fact

BIOTECH GROWTH N V filed Form 4 for Black Diamond Therapeutics, Inc. (BDTX) on 20 Mar 2025.

Key facts

This page summarizes BIOTECH GROWTH N V's Form 4 filing for Black Diamond Therapeutics, Inc. (BDTX).
7 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 20 Mar 2025, 21:01.

Change

Previous filing in this sequence was filed on 05 Nov 2024.
Current net transaction value: -$11,997,749.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDTX transaction

Common Stock

Sale

Transaction value: $2,069,100
Shares: -1,000,000
Change %: -12%
Price: $2.07
Shares after: 7,517,839
Date: 19 Mar 2025
Ownership: Direct

BDTX transaction

Common Stock

Sale

Transaction value: $582,900
Shares: -300,000
Change %: -4%
Price: $1.94
Shares after: 7,217,839
Date: 19 Mar 2025
Ownership: Direct

BDTX transaction

Common Stock

Sale

Transaction value: $2,308,100
Shares: -1,000,000
Change %: -14%
Price: $2.31
Shares after: 6,217,839
Date: 19 Mar 2025
Ownership: Direct

BDTX transaction

Common Stock

Sale

Transaction value: $4,000,800
Shares: -2,000,000
Change %: -32%
Price: $2.00
Shares after: 4,217,839
Date: 19 Mar 2025
Ownership: Direct

BDTX transaction

Common Stock

Sale

Transaction value: $837,160
Shares: -400,000
Change %: -9.5%
Price: $2.09
Shares after: 3,817,839
Date: 19 Mar 2025
Ownership: Direct

BDTX transaction

Common Stock

Sale

Transaction value: $1,141,239
Shares: -584,292
Change %: -15%
Price: $1.95
Shares after: 3,233,547
Date: 19 Mar 2025
Ownership: Direct

BDTX transaction

Common Stock

Sale

Transaction value: $1,058,450
Shares: -500,000
Change %: -15%
Price: $2.12
Shares after: 2,733,547
Date: 19 Mar 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

BIOTECH GROWTH N V is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

SEC remarks

Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Black Diamond Therapeutics, Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.